[1] 国家药品不良反应监测中心.《关于发布< 常见严重药品不良反应技术规范及评价标准> 的通知》(监测与评价综[2010]26号)[EB/OL].[2013-03-01]. http://www.cdr.gov.cn/. [2] Benichou C.Criteria of drug-induced liver disorders.Report of an international consensus meeting[J].J Hepatol,1990,11(2):272-276. [3] Hilleman D, Miller M A, Parker R, et al. Optimal management of amiodarone therapy:efficacy and side effects[J]. Pharmacotherapy, 1998, 18(6):138S-145S. [4] 黄兴福,杨艳敏,朱俊. 静脉胺碘酮与严重肝功能损害[J].中国心脏起搏与心电生理杂志,2009,23(6):477-479. [5] Kaufmann P, Torok M, Hanni A, et al. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology[J].2005,41(4):925-935. [6] Breuer H W, Bossek W, Haferland C, et al. Amiodarone-induced severe hepatitis mediated by immunological mechanisms[J]. Int J Clin Pharmacol Ther, 1998, 36(6):350-352. [7] Tisdale J E, Follin S L, Ordelova A, et al. Risk factors for the development fo specific noncardiovascular adverse effects associated with amiodarone[J]. J Clin Pharmacol, 1995, 35(4):351-356. [8] Eowey P R, Marmchak R A, Rial S J, et al. Intervenous amiodarone[J]. JACC, 1997, 29(4): 1190-1198. [9] Fransi S, Briedis J.Anaphylaxis to intravenous amiodarone [J].Anaesth Intensive Care, 2004, 32(4):578-579. [10] 罗心平,施海明,朱军,等. 9例静脉注射胺碘酮不良反应的临床分析[J]. 中国临床药学杂志,2001,10(6):384-386. [11] 朱俊.胺碘酮的临床应用[J].医师进修杂志, 2004, 27(1):45-47. |